Taysha Gene Therapies: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Taysha Gene Therapies (NASDAQ:TSHA) reported Q4 earnings with an EPS of $0.92, beating estimates by 936% and showing a revenue increase of $1.10 million from the previous year. Despite past earnings misses, the company's share price increased by 26% following the last quarterly report.
March 19, 2024 | 8:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Taysha Gene Therapies reported a significant Q4 earnings beat with an EPS of $0.92, far exceeding the estimated -$0.11, and a year-over-year revenue increase of $1.10 million.
The substantial earnings beat and revenue increase reported by Taysha Gene Therapies are likely to positively impact investor sentiment and the stock price in the short term. Historically, the company's stock price increased by 26% following the last quarterly report, indicating a positive market reaction to strong earnings performances.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100